Is Kwality Pharma overvalued or undervalued?

As of 21 May 2025, the valuation grade for Kwality Pharma has moved from expensive to fair, indicating a more favorable assessment of its stock price. The company is currently fairly valued, with a PE ratio of 24.19, an EV to EBITDA of 13.20, and a PEG ratio of 0.63, suggesting that it is priced appropriately relative to its growth prospects. In comparison to its peers, Kwality Pharma's PE ratio aligns closely with the industry average, while its EV to EBITDA is competitive, indicating a solid position within the pharmaceuticals and biotechnology sector. Notably, companies like Sun Pharmaceutical Industries have a PE of 30.00, while Dr. Reddy's Laboratories stands at 25.00, highlighting that Kwality Pharma is relatively more attractive in terms of valuation. Additionally, the company's recent stock performance has outpaced the Sensex over the past year, with a return of 64.07% compared to the Sensex's 7.59%, reinforcing the notion that it is fairly valued at this stage.